PLRX News and Press, Pliant Therapeutics Inc. From 04/07/25

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California ...

2025-04-03 12:22:51 ET Summary Pliant Therapeutics suffered a major setback with its lead drug candidate, causing its stock to plummet well below its cash value. Activist investor Kevin Tang has acquired a significant stake in PLRX, aiming to capitalize on the company's large cash...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Pliant Therapeutics stock or options and wo...

Antitumor activity observed with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeut...

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics PR Newswire Faruqi & Faruqi, LLP Securities...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. ...

2025-03-04 10:32:18 ET More on Pliant Therapeutics Pliant Therapeutics: Strange Volatility Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF Pliant stock jumps 28% on bexotegrast study update Seeking Alpha’s Quant Rating on Pliant Th...

Veritec, Inc. (VRTC) is expected to report for quarter end 2024-12-31 Nayax Ltd. (NYAX) is expected to report $0.04 for Q4 2024 CrowdStrike Holdings Inc. (CRWD) is expected to report $0.01 for Q4 2025 Schaeffler AG Bearer Preference Shares (SCFLF) is expected to report for quarter end...

2025-03-03 17:05:08 ET More on Pliant Therapeutics Pliant Therapeutics: Strange Volatility Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF Pliant stock jumps 28% on bexotegrast study update Seeking Alpha’s Quant Rating on Pliant Th...

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeu...